Related Experiment Videos
Tumor removal enhances immunity induced by B7.1
1Department of Pathology and Cancer Research Institute, Seoul National University College of Medicine, Korea.
Summary
B7.1 gene transfer into a poorly immunogenic tumor (MMSV) prevented tumor growth and induced anti-tumor immunity. Vaccination with MMSV-B7.1 after tumor removal protected against tumor recurrence, suggesting a potential cancer vaccine strategy.
Area of Science:
- Immunology
- Oncology
- Gene Therapy
Background:
- Costimulation via B7.1 is crucial for T cell-mediated anti-tumor immunity.
- Moloney murine sarcoma virus-induced tumor cell line (MMSV) is poorly immunogenic.
Purpose of the Study:
- To assess the anti-tumor effects of B7.1 gene transfer into MMSV.
- To evaluate the potential of MMSV-B7.1 as a cancer vaccine.
Main Methods:
- Constructed a stable B7.1 gene transfectant of MMSV (MMSV-B7.1).
- Injected MMSV-B7.1 alone or with wild-type MMSV into syngeneic mouse models.
- Administered MMSV-B7.1 vaccination post-surgical tumor removal followed by tumor cell re-challenge.
Main Results:
- MMSV-B7.1 transfectants did not cause tumor development.
- Co-injection with wild-type MMSV led to tumor-free status in 50% of mice, increased T cells, upregulated cytokines (IL-4, IL-5, IL-10, IL-13, IL-15, IFN-gamma), and rejection of reinjected MMSV.
- Post-surgical vaccination with MMSV-B7.1 conferred complete protection against tumor recurrence upon re-challenge.
Conclusions:
- B7.1 gene transfer can elicit potent anti-tumor immunity.
- B7.1 vaccination following tumor removal shows promise for preventing tumor recurrence.